Table 2.
Best response rates using RECIST 1.1 and mRECIST criteria of assessment in patients with baseline and post‐therapeutic cavitation
| Response | RECIST 1.1 | mRECIST | ||||
|---|---|---|---|---|---|---|
| No. of patients (%) | Median PFS (months) | P | No. of patients (%) | Median PFS (months) | P | |
| Patients with baseline cavitation | 0.076† | 0.550† | ||||
| PR | 8 (15.7) | 4.5 | 0.409‡ | 14 (27.5) | 6.4 | 0.258‡ |
| SD | 32 (62.7) | 8.2 | 0.574§ | 17 (33.3) | 8.2 | 0.913§ |
| PD | 11 (21.6) | 4.3 | 0.012¶ | 20 (39.2) | 5.0 | 0.407¶ |
| PR + SD | 40 (78.4) | 7.9 | 0.657†† | 31 (60.8) | 8.0 | 0.549†† |
| SD + PD | 43 (84.3) | 7.3 | 0.032‡‡ | 37 (72.5) | 6.5 | 0.575‡‡ |
| PR + PD | 19 (37.3) | 4.3 | 0.053§§ | 34 (66.7) | 6.2 | 0.276§§ |
| Patients with post‐therapeutic cavitation | 0.477† | 0.004† | ||||
| PR | 2 (8.7) | 4.9 | 0.200‡ | 15 (65.2) | 8.0 | 0.566‡ |
| SD | 12 (52.2) | 6.9 | 0.557§ | 2 (8.7) | 12.9 | 0.003§ |
| PD | 9 (39.1) | 3.6 | 0.507¶ | 6 (26.1) | 3.5 | 0.034¶ |
| PR + SD | 14 (60.9) | 6.6 | 0.298†† | 17 (73.9) | 8.7 | 0.184†† |
| SD + PD | 21 (91.3) | 4.8 | 0.972‡‡ | 8 (34.8) | 3.6 | 0.001‡‡ |
| PR + PD | 11 (47.8) | 3.6 | 0.369§§ | 21 (91.3) | 4.7 | 0.373§§ |
†
PR versus SD versus PD.
‡
PR versus SD.
§
PR versus PD.
¶
SD versus PD.
††
PR versus (SD + PD).
‡‡
(PR + SD) versus PD.
§§
SD versus (PR + PD).
mRECIST, modified Response Evaluation Criteria in Solid Tumors; PD, progressive disease; PFS, progression‐free survival; PR, partial response; SD, stable disease.